Pharma feed

N
Kite Pharma Inc
Motley Fool· 17 Feb 2019

2 Healthcare Stocks Ripe for a Takeover

The healthcare sector has a well-earned reputation for ultra-pricey acquisitions. In 2017, for example, Gilead Sciences paid nearly $12 billion for Kite Pharma and its commercially unproven cell therapy platform. Kicking off this year, Bristol-Myers Squibb struck a $74 billion deal to acquire biotech heavyweight Celgene.

  • Kite Pharma Inc
  • Gilead Sciences, Inc.
  • M&A Activities
  • News Articles
  • News and Other Websites
N
Bayer AG
Evotec· 16 Feb 2019

Evotec and Bayer enter into multi-target alliance to fight endometriosis

01.10.2012 10:35 Hamburg, Germany: Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) that Evotec and Bayer Pharma AG have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis.

  • Bayer AG
  • Bayer Pharma AG
  • Evotec AG
  • Partnerships & Alliances
  • News Articles
  • News and Other Websites
N
Bayer AG
Evotec· 16 Feb 2019

Evotec achieves clinical development milestone as part of its multi-target alliance with Bayer in endometriosis

Hamburg, Germany, 04 August 2016: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that it has reached a milestone from Bayer for the progression of a programme from the alliance portfolio into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec.

  • Bayer AG
  • Evotec AG
  • Partnerships & Alliances
  • News Articles
  • News and Other Websites
N
Bayer AG
Evotec· 16 Feb 2019

Evotec receives pre-clinical milestone as part of its Endometriosis Alliance with Bayer

ABOUT ENDOMETRIOSIS Endometriosis affects an estimated 176 million women worldwide or 10% of women of reproductive age. It is caused by the abnormal growth of tissue similar to that which lines the uterus (endometrial tissue) in locations outside of the uterine cavity, where it causes ectopic lesion growth and debilitating pain.

  • Evotec AG
  • Bayer AG
  • Partnerships & Alliances
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
Seeking Alpha· 16 Feb 2019

FDA OKs expanded use for Merck's Keytruda

The FDA has approved Merck's (NYSE:MRK) Keytruda (pembrolizumab) for the adjuvant treatment of melanoma patients with lymph node involvement following complete resection, its 17th U.S. indication.

  • Merck & Co., Inc.
  • OKS Group
  • Regulatory & Legal
  • News Articles
  • News and Other Websites
  • Pfizer Inc.
  • Digital Science
  • Awards & Recognitions
  • Social Updates
  • Twitter
Daiichi Sankyo Co Ltd
American Regent· 16 Feb 2019

Process Supervisor of Manufacturing, 3:00pm - 11:30pm Job in Shirley, NY for Luitpold Pharmaceuticals, Inc.

Job Attributes Job ID 1993 Location Shirley, NY Category Manufacturing/Production/Operations Department Production Overhead Business Unit NY Process Supervisor of Manufacturing, 3:00pm - 11:30pm Apply NEW SEARCH In Shirley, NY Luitpold Pharmaceuticals, Inc., a Daiichi Sankyo Group Company, is dedicated to the development and marketing of innovative, quality drugs for healthcare professionals, clinics, and hospitals across the United States and Canada.

  • Daiichi Sankyo Co Ltd
  • Luitpold Pharmaceuticals Inc
  • New Offerings
  • Company Websites
Gilead Sciences, Inc.
Pharmaceutic Litho· 16 Feb 2019

Gilead Sciences and Kite To Acquire Cell Design Labs · Pharmaceutic Litho & Label Company

Gilead Sciences, Inc. and its cell therapy subsidiary Kite have entered into a definitive agreement to acquire Cell Design Labs, Inc., gaining new technology platforms that will enhance research and development efforts in cellular therapy. Under the terms of the agreement, Gilead will acquire all of the outstanding shares of Cell Design Labs, which includes the approximately 12.2 percent of shares of Cell Design Labs that are currently held by Kite, for up to approximately $567 million.

  • Gilead Sciences, Inc.
  • Pharmaceutic Litho & Label
  • M&A Activities
  • Press Releases
  • Company Websites
Mylan Specialty LP
Pharmaceutic Litho· 16 Feb 2019

Mylan Launches Generic Version Of The Novartis Exelon Patch · Pharmaceutic Litho & Label Company

Mylan N.V. today announced the U.S. launch of Rivastigmine Transdermal System, 4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3 mg/24 hrs, a generic version of Novartis’ Exelon Patch. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of dementia associated with mild, moderate and severe Alzheimer’s disease and the treatment of mild to moderate dementia associated with Parkinson’s disease.

  • Mylan Specialty LP
  • Novartis AG
  • Pharmaceutic Litho & Label
  • New Offerings
  • Press Releases
  • Company Websites
Merck & Co., Inc.
Pharmaceutic Litho· 16 Feb 2019

Chasing top HIV players, Merck scores FDA approval for 2 new drugs · Pharmaceutic Litho & Label Company

After marquee HIV drug approvals last year for Gilead and GlaxoSmithKline, Merck will follow into the crowded market with two new meds. The drugmaker scored FDA approvals for a new non-nucleoside reverse transcriptase inhibitor called doravirine, both alone and in a combo with other HIV therapies.

  • Merck & Co., Inc.
  • Pharmaceutic Litho & Label
  • Regulatory & Legal
  • Press Releases
  • Company Websites
Merck & Co., Inc.
Plexxikon· 16 Feb 2019

Plexxikon and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-oncology Regimen

Press Releases Plexxikon and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-oncology Regimen Study will Evaluate Merck’s Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab), in Combination with Plexxikon’s PLX3397 Berkeley, CA, and Kenilworth, N.J.

  • Plexxikon Inc
  • Merck & Co., Inc.
  • Partnerships & Alliances
  • Press Releases
  • Company Websites
Merck & Co., Inc.
Gcs-Web· 16 Feb 2019

Ra Pharmaceuticals Receives Development Milestone Payment Under Agreement with Merck

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 6, 2018-- Ra Pharmaceuticals, Inc. (NASDAQ:RARX) today announced that it has received a development milestone payment under its collaboration agreement with Merck, known as MSD outside the US and Canada . The milestone payment is associated with the companies’ collaboration for a non-complement cardiovascular target with a large market opportunity.

  • Ra Pharmaceuticals
  • Merck & Co., Inc.
  • Cambridge Group
  • Partnerships & Alliances
  • Press Releases
  • Company Websites
N
Sanofi
The Hindu· 16 Feb 2019

HC refuses to quash case against pharma firm

The Karnataka High Court on Friday declined to quash criminal proceedings against Sanofi India Ltd., a pharmaceutical company, by the Central Bureau of Investigation (CBI) for allegedly cheating the Bhabha Atomic Research Centre (BARC), Mysuru, of ₹3.53 lakh during 2012-15 by conspiring with a scientific officer of the BARC.

  • Research Centre Ltd
  • Sanofi
  • Regulatory & Legal
  • News Articles
  • News and Other Websites
Catalent Inc
Tradeandindustrydev· 16 Feb 2019

IN: Catalent Inc. to Expand in Bloomington, Create Up to 200 New Jobs

IN: Catalent Inc. to Expand in Bloomington, Create Up to 200 New Jobs 15 Feb, 2019 The state of Indiana and the city of Bloomington announced that Catalent, Inc., a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has commenced a significant expansion of its biologics manufacturing operations in Bloomington, with plans to create up to 200 new jobs by the end of 2024.

  • Catalent Inc
  • Business Expansion
  • News Articles
  • Company Websites
N
Pfizer Inc.
FirstWord Pharma· 16 Feb 2019

Pfizer signs cooperation agreement with SZTE

Pfizer entered into an agreement with the University of Szeged in Hungary that will allow the university's patients to be able to access the most modern therapies, reported the Budapest Business Journal. According to the news source, the university achieved clinical trial center certification under the "Pfizer Inspire" program in October 2018, becoming a part of the company's special network.

  • Pfizer Inc.
  • Partnerships & Alliances
  • News Articles
  • News and Other Websites
Regeneron Pharmaceuticals Inc
Regeneron· 16 Feb 2019

U.S. and EU Patent Office Decisions Invalidate Amgen Subsidiary Immunex's Patents Claiming Antibodies to the IL-4 Receptor

TARRYTOWN, N.Y. , Feb. 15, 2019 /PRNewswire/ -- Today the European Patent Office invalidated Immunex's European patent claiming antibodies that target human IL-4 receptors (IL-4R) Decision follows yesterday's ruling by the U.S. Patent & Trademark Office invalidating a similar Immunex patent claiming antibodies that target human IL-4R Regeneron Pharmaceuticals, Inc.

  • Regeneron Pharmaceuticals Inc
  • Amgen, Inc.
  • Immunex Corp
  • New Offerings
  • Press Releases
  • Company Websites
Regeneron Pharmaceuticals Inc
Regeneron· 15 Feb 2019

Regeneron Announces Upcoming Investor Conference Presentation

TARRYTOWN, N.Y. , Feb. 14, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its management presentation at the Cowen 39th Annual Healthcare Conference at 11:20 a.m. ET on Monday, March 11, 2019 . The session may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events.cfm.

  • Regeneron Pharmaceuticals Inc
  • Cowen Group
  • Events
  • Company Websites
Pfizer Inc.
C3i Solutions· 15 Feb 2019

C3i Solutions and Pfizer Consumer Health Named as Finalists in the 13th Stevie Awards for Sales & Customer Service

news C3i Solutions and Pfizer Consumer Health Named as Finalists in the 13th Stevie Awards for Sales & Customer Service C3i Solutions and Pfizer Consumer Health were named Finalists the Customer Service Outsourcing Provider of the Year category in the 13th annual Stevie® Awards for Sales & Customer Service.

  • Pfizer Inc.
  • C3i Inc
  • Telerx
  • Awards & Recognitions
  • Press Releases
  • Company Websites
N
Eli Lilly and Co
FirstWord Pharma· 15 Feb 2019

Bayer acquires full rights to Vitrakvi, LOXO-195 from Eli Lilly's Loxo Oncology

Bayer said Friday that it has exercised its option to obtain full licensing rights for Vitrakvi (larotrectinib) and BAY 2731954, previously known as LOXO-195, which are being developed to treat adult and paediatric patients with advanced solid tumours harbouring NTRK gene fusions.

  • Eli Lilly and Co
  • Loxo Oncology, Inc.
  • Bayer AG
  • Procurement & Sales
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
FirstWord Pharma· 15 Feb 2019

FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA (pembrolizumab) in Combination with Inlyta (axitinib) as First-Line Treatment for Advanced Renal Cell Carcinoma

FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA (pembrolizumab) in Combination with Inlyta (axitinib) as First-Line Treatment for Advanced Renal Cell Carcinoma

  • Merck & Co., Inc.
  • Biologics, Inc.
  • Regulatory & Legal
  • News Articles
  • News and Other Websites
N
Sanofi
Healthcare IT News· 15 Feb 2019

HIMSS launches DIAM for Enterprise Imaging, Sanofi appoints chief digital officer, and more news briefs

HIMSS Analytics unveils new benchmarking model at HIMSS19. HIMSS Analytics has announced at HIMSS19 in Orlando that it is introducing the Digital Imaging Adoption Model for Enterprise Imaging - an eight-stage model aiming to help experts benchmark the use of IT in medical imaging.

  • Sanofi
  • Management Changes
  • New Offerings
  • News Articles
  • News and Other Websites
Twitter· 15 Feb 2019

Bayer acquires full rights to Vitrakvi, LOXO-195 from Eli Lilly's Loxo Oncology https://t.co/WEOA2LBhH9

Bayer acquires full rights to Vitrakvi, LOXO-195 from Eli Lilly's Loxo Oncology
Bayer said Friday that it has exercised its option to obtain full licensing rights for Vitrakvi (larotrectinib) and BAY 2731954, previously known as LOXO-195, which are being de...
  • Eli Lilly and Co
  • FirstWord Pharma
  • Bayer AG
  • Procurement & Sales
  • Social Updates
  • Twitter
  • AANA (American Association of Nurse Anesthetists)
  • Merck & Co., Inc.
  • Events
  • Social Updates
  • Twitter
N
Bayer AG
FirstWord Pharma· 15 Feb 2019

Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195)

Bayer exercised option under change-in-control clause in it’s agreement with Loxo Oncology to obtain full licensing rights for the two TRK inhibitor agents / Bayer to be solely responsible for the global development and commercialization of both larotrectinib and BAY 2731954 (LOXO-195) / Co-Promotion in the U.S.

  • Bayer AG
  • Procurement & Sales
  • News Articles
  • News and Other Websites
Twitter· 15 Feb 2019

Pharma and biotech companies strengthen their leadership teams with new hires and appointments at Cadent, bluebird, Abeona, Sanofi, and more. Here is our weekly Moves & Shakers article on leadership changes. https://hubs.ly/H0gD3dR0

BioSpace Movers and Shakers: Feb. 15
Cadent Therapeutics – Longtime industry veteran Jodie Morrison was named the new chief executive officer for Cambridge, Mass.-based Cadent Therapeutics. Morrison takes over as C...
  • Sanofi
  • Biospace
  • Partnerships & Alliances
  • Social Updates
  • Twitter
1 2 3 4 5